Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 15,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
1,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

NCT07220785
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Mibavademab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

NCT05869643
View directory record Official record
Conditions
HIV-1-infection
Interventions
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
Drug
Lead sponsor
ST Pharm Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Ft. Pierce, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens

NCT05036343
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

NCT00886626
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Exenatide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

NCT00430092
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
219 participants
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 29, 2026, 3:26 PM EDT
Suspended Phase 2Phase 3 Interventional

Ankle Manual Therapy for Ankle Sprains

NCT00888498
View directory record Official record
Conditions
Sprains and Strains
Interventions
Passive Positioning, High-Velocity, Low-Amplitude Stretch, Slow, Mobilization Stretch
Other
Lead sponsor
University of the Pacific
Other
Eligibility
16 Years to 60 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 29, 2026, 3:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants

NCT07765706
View directory record Official record
Conditions
Healthy Volunteers
Interventions
INS1033, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Terminated Phase 4 Interventional

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

NCT05191706
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone, Prednisolone Acetate Ophthalmic
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
Up to 3 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Huntington Beach, California • Palo Alto, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Terminated Phase 4 Interventional Results available

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

NCT00086684
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Pentosan polysulfate sodium 100 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752
View directory record Official record
Conditions
Multiple Myeloma, Renal Insufficiency
Interventions
BHQ880, BHQ880 Placebo, bortezomib, dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 3 Interventional

The Efficacy of Oral Steroids in the Treatment of Acute Sciatica

NCT00317447
View directory record Official record
Conditions
Sciatica
Interventions
Oral Prednisone
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
20 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2006 · Synced Oct 29, 2026, 3:26 PM EDT
Not yet recruiting Not applicable Interventional

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses

NCT06084247
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
Curved KARL STORZ fetoscope, Conventional Scopes
Device
Lead sponsor
Jimmy Espinoza
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 29, 2026, 3:26 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

NCT05207085
View directory record Official record
Conditions
Trichotillomania (Hair-Pulling Disorder)
Interventions
Valbenazine Oral Capsule, Placebo Oral capsule
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 29, 2026, 3:26 PM EDT
Terminated Not applicable Interventional Results available

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

NCT01718444
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

NCT01904409
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-004, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

NCT01475734
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

NCT04238364
View directory record Official record
Conditions
Healthy Volunteers
Interventions
EI-1071, Placebo
Drug
Lead sponsor
Elixiron Immunotherapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 3:26 PM EDT
Terminated Not applicable Interventional Results available

Oxytocin Add on Study for Stable Schizophrenic Patients

NCT00506909
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
David Feifel
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 29, 2026, 3:26 PM EDT
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00691964
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABT-874, etanercept, placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 29, 2026, 3:26 PM EDT